Subject: Gardasil Pediatric Utilization and Safety Review for Pediatric Advisory Committee Meeting On June 8, 2006, the US Food and Drug Administration approved the first vaccine against the human papillomavirus (HPV). Gardasil was initially licensed for females aged 9–26 years for the prevention of cervical cancer and precancerous lesions, as well as genital warts […]
November 11, 2010 Analysis of VAERS Reports
Found 21,022 events where Vaccine is HPV, HPV2, and HPV4. All HPV VACCINES COMBINED Found 89 events where Vaccine is HPV, HPV2, and HPV4 and Patient Died. View report here.
PATIENT INFORMATION ABOUT GARDASIL
What important information about GARDASIL should I know? You should continue to get routine cervical cancer screening. GARDASIL may not fully protect everyone who gets the vaccine. GARDASIL will not protect against HPV types that you already have. Who should not get GARDASIL? You should not get GARDASIL if you have, or have had: […]
Gardasil Safety: Post-marketing Experience
CONTRAINDICATIONS Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous dose of GARDASIL. WARNINGS AND PRECAUTIONS Syncope Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination […]
Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females
This study is currently recruiting participants. Verified by Emory University, February 2010 Official Title Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents Purpose African American adolescent females seeking treatment for STIs are an underserved population at increased risk for HPV infection. While GARDASIL is an effective preventive vaccine, vaccination rates are low. […]
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 57
- Next Page »